Biodesix, Inc. (NASDAQ:BDSX) is a diagnostic solutions company that operates within the Zacks Medical Services industry. The company focuses on providing innovative diagnostic tests to improve patient outcomes. Biodesix has been gaining attention due to its recent financial performance and stock upgrades. Competitors in the medical diagnostics field include companies like Exact Sciences and Guardant Health.
On February 27, 2026, William Blair upgraded Biodesix's stock from Market Perform to Outperform, with the stock priced at $14.22. This upgrade comes as Biodesix shows significant improvement in its financial metrics. The company reported a quarterly loss of $0.49 per share, which was much better than the expected $1.05 loss, resulting in an earnings surprise of 53.33%.
Biodesix's revenue for the quarter ending December 2025 was $28.76 million, surpassing the Zacks Consensus Estimate by 14.11%. This represents a substantial increase from the $20.43 million reported a year ago. The company has consistently exceeded revenue estimates, doing so three times in the last four quarters, highlighting its strong performance in the industry.
The company achieved a remarkable 41% revenue growth and an 83% gross margin in the fourth quarter of 2025. Additionally, Biodesix improved its net loss by 52% and achieved its first-ever Adjusted EBITDA positivity. For fiscal year 2026, Biodesix has provided a revenue guidance of $106 to $112 million, with the midpoint reflecting a 23% growth, as highlighted by CEO Scott Hutton.
Currently, BDSX is priced at $14.22, marking a 9.98% increase with a change of $1.29. The stock has fluctuated between $12.36 and $14.22 today. Over the past year, it reached a high of $19.14 and a low of $3.44. The company's market capitalization is approximately $113.13 million, with a trading volume of 120,970 shares on the NASDAQ exchange.
